Interferon in polycythemia vera
Brian Edwards
Patient blood management in 2023
Anders Poulsen
Fixed-duration versus continuous therapy in CLL
John Edwards
Quadruplet induction for newly diagnosed myeloma
Johannes Schmitt
Myeloproliferative neoplasms: diagnosis and risk assessment
Gang Gao
Transfusion medicine: first-line treatment
William Jackson
Chronic lymphocytic leukemia: first-line treatment
Anna Lehmann
Myeloma and plasma cell disorders: controversies and case discussion
Alejandro Torres
Myeloproliferative neoplasms: long-term follow-up
Ana Costa
Transfusion medicine: first-line treatment
Miriam Schröder
Chronic lymphocytic leukemia: long-term follow-up
Akiko Kimura
Myeloma and plasma cell disorders: first-line treatment
Martin Keller
Health-related quality of life in adults with Philadelphia chromosome-positive ALL: a prospective british study
Mihai Popa
Single-cell profiling reveals leukemic stem cell persistence in acute myeloid leukemia (AML)
Élodie Guerin
Long-term outcomes of adults with immune thrombocytopenia treated with emicizumab prophylaxis: a Italian registry study of 188 patients
Michael Baker
Nelbrutinib plus fixed-duration venetoclax in relapsed CLL after covalent BTK inhibitors: randomized phase 3 results of the MERIDIAN-6 trial
Sophie de Vries
Ravelinib plus imatinib in chronic-phase CML in deep molecular response: phase 3 results of the VALOR-8 trial
Anja Peters
Multi-omic characterization of inflammatory aging of the stem cell niche in patients with clonal hematopoiesis of indeterminate potential
Jürgen Schulz
Real-world effectiveness of zelvudocel in adolescents and young adults with ALL: a multicenter multinational cohort
Johannes Weber
Real-world effectiveness of menavostat in adults with newly diagnosed AML receiving intensive induction: a multicenter multinational cohort
Anja Weber
Concivumab plus direct oral anticoagulants in hemophilia B: randomized phase 2 results of the NORDLYS-4 trial
Hyun-woo Choi
Multi-omic characterization of BCR signalling rewiring in treatment-naive CLL
Jessica Harris
Nk-501 plus busulfan myeloablation in patients receiving CD19-directed CAR T-cell therapy: randomized phase 3 results of the TRIDENT-5 trial
Adam Mazur
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Julia Williams
Single-cell profiling reveals leukemia-niche interactions in acute lymphoblastic leukemia (ALL)
Christina Braun
Real-world effectiveness of ravotuzumab vedotin in newly diagnosed AML patients ineligible for intensive chemotherapy: a multicenter nordic cohort
Mathieu Girard
Multi-omic characterization of tissue factor pathway regulation in hemophilia B
Thomas Huber
Health-related quality of life in treatment-naive CLL: a prospective british study
Christian Lorenz
Single-cell profiling reveals immune effector cell-associated neurotoxicity in gene and cell therapy
Despoina Papageorgiou
Prognostic value of HSC quiescence markers in healthy donors: results from SAGA-6
Florian Koch
Health-related quality of life in NPM1-mutated AML: a prospective german study
Olivier David
Health-related quality of life in adults with newly diagnosed AML receiving intensive induction: a prospective french study
Johanna Krüger
Treatment patterns and survival in people with severe hemophilia A: real-world data from the Nordic hemostasis registry
Mikko Heinonen
Ravelinib versus dasatinib in chronic-phase CML in deep molecular response (SAGA-2): a randomized phase 3 trial
Jessica Roberts
Targeting immune effector cell-associated neurotoxicity in gene and cell therapy: preclinical evidence
Paola Rinaldi
Prognostic value of TP53 status in relapsed or refractory large B-cell lymphoma: results from SUMMIT-1
Andrea Wagner
Menin-kmt2a dependency predicts outcome in older adults with secondary AML
Daniel Schulz
Efficacy and safety of rilvabrutinib in people with severe hemophilia A: primary analysis of the randomized phase 3 ECLIPSE-1 study
Dana Rosenberg
Treatment patterns and survival in people with severe hemophilia A: real-world data from the Italian hemostasis registry
Pavel Novák
Targeting treatment-free remission biology in chronic myeloid leukemia (CML): preclinical evidence
Arnaud Bernard
Real-world effectiveness of lovotigene autotemcel in patients with sickle cell disease treated with gene editing: a multicenter french cohort
Alexander Neumann
Brexalucel plus Pola-R-CHP in classic Hodgkin lymphoma: randomized phase 2 results of the CORONA-9 trial
Claire Bennett
Treatment patterns and survival in adults with newly diagnosed AML receiving intensive induction: real-world data from the multinational AML registry
Sophie Dekker
Efactocog beta versus low-molecular-weight heparin in patients with antiphospholipid syndrome (ARCTIC-4): a randomized phase 2 trial
Silvia Leone
Multi-omic characterization of neutrophil extracellular traps in thrombosis in people with severe hemophilia A
Fatma Özkan
Orvematinib versus imatinib in chronic-phase CML in deep molecular response (SAGA-3): a randomized phase 2 trial
Claudia Meier
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Daniel Lehmann
Real-world effectiveness of glovutamab in primary CNS lymphoma: a multicenter german cohort
Michael Bauer
Nordheim Pharma Satellite Symposium: Redefining depth of response in multiple myeloma
Fatma Özdemir, Henrik Bakken, Wei Lin
Corvalis Biotherapeutics Satellite Symposium: Bispecific antibodies across lines of therapy in B-cell lymphoma
Anders Poulsen, Marie Winkler, Dimitrios Makris
Hemavera Therapeutics Satellite Symposium: Iron, inflammation and anemia: new targets
Jan Möller, Julie Garcia, Jorge Álvarez
Late effects after childhood ALL
Luca Vitale
Artificial intelligence in the hematology laboratory
Dimitrios Makris
Primary CNS lymphoma
Takuya Kato
Non-factor therapies in hemophilia
Henrik Bakken
Acute lymphoblastic leukemia: managing relapse
Brian Wilson
Novel technologies and AI: emerging therapies
Martina Rinaldi
Lymphoma: managing relapse
Jessica Turner
Bleeding, thrombosis and platelets: controversies and case discussion
Ece Şimşek
Acute lymphoblastic leukemia: first-line treatment
Rahul Patel
Novel technologies and AI: managing relapse
Camilla Kristensen
Lymphoma: managing relapse
Antonio Bianco
Bleeding, thrombosis and platelets: diagnosis and risk assessment
Daniel Brown
Opening plenary lecture: Hematology at the frontier of cell and gene therapy
Jan Jung
Plenary lecture: Clonal hematopoiesis, aging and disease
Wei Lin